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HYPERTENSION AND LIPID ABNORMALITIES 
INTRODUCTION 
                  Earliest references about  Hypertension  are   seen   in  Chinese    
books written about 2600 B.C. Until prior   to  twentieth  century there 
were   no   clinical    instrument for measuring  blood  pressure non 
invasively. However the presence of high blood   pressure had  long  been   
recognized  by  the degree of  “ hardness  of  arteries ”. Even though the 
association of high blood   pressure   and major     cardio-   vascular events  
like  stroke  and  cardiac  failure    were   recognized   by    ancient            
physicians  like  Hippocrates  and  Galen,  the  real  breakthrough came in 
the early twentieth  century  after  the  introduction  of   non-invasive   BP  
monitoring   with sphygmomanometer by Riva Roci1 and Koratkoff. 
Further insights into variation of BP in humans under the effect of exercise, 
stress,  emotion and     the    complication of  longstanding  hypertension  
were  made  possible.  Today    hypertension has been recognized as the 
most common cardiovascular disorder2. It is the leading cause of morbidity 
and mortality in both developing and developed countries3. 
                   Hypertension  is  one  of  the  ten leading reported causes of 
death with about 4% of such death due to hypertensive  complications 4 . 
The risk features that have  been  associated  with  hypertension  include  
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increased salt  intake, Diabetes mellitus, Cigarette smoking, elevated serum 
lipids, sedentary lifestyle ,  diet rich in saturated fats , genetic factors and 
stress 5 
                         Though the association of hypertension & dyslipidemia  is 
common and been proved by various studies beyond doubt, the reason for 
this co-occurrence has not been probed  out  yet . Three possible 
mechanisms are proposed for this but none have been proven. 
1. Dyslipidemia can increase the incidence of Hypertension. 
2. Hypertension can increase the incidence of  Dyslipidemia. 
3. There may be a common factor which cause increased incidence of both. 
                             This study is conducted to assess the abnormalities in 
plasma lipid profile of hypertensive patients and to determine the factors 
influencing it. 
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AIM OF STUDY 
 
• To study the prevalence and  pattern  of  lipid  profile abnormalities in 
newly diagnosed hypertensive  patients. 
• To study the influence  of  various clinical, demographic ,  social and 
socioeconomic parameters on  lipid  profile abnormalities in hypertensive 
patients. 
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REVIEW OF LITERATURE 
HYPERTENSION 
EPIDEMIOLOGY AND RISKS 
                                         Approximately 1 billion people worldwide are 
affected by hypertension 6. There are however important differences in 
prevalence between population and ethnic groups 7. The Framingham Heart 
study has estimated that individuals normotensive at age 55 years have 90 
% lifetime risk of developing hypertension 8. The fourth National Health 
and Nutrition examination survey (NHANES IV) showed an overall 
prevalence of  hypertension 28.7 % of United States population . The 
prevalence varied from 7.2% in those aged 18- 39 years to 65.4 % in those 
aged 6 years and older. It was greater in women ( 30 .1 % ) than in men ( 
27.1 % ) 
                Hypertension represents a potent risk factor for cardiovascular, 
peripheral vascular and renal diseases 9,10,11,12,13. The relationship is strong, 
continuous and gradual. A 36 year follow up from Framingham Heart study 
showed that hypertension is associated with 2 to 4 fold increase in the risk 
for the development of coronary heart disease, cardiac failure and overall 
cardiovascular events in both men and women. 
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                      The Framingham study also predicts a 1.7 fold increase in the 
risk of stroke per S.D increment in women and 1.9 fold increase in risk per 
S.D increment in men at age 6O.It also showed  peripheral arterial disease 
risk to increase dramatically by 3 fold in males and 4 fold in females. 
                    The relation of increasing BP levels to incidence of ESRD is 
well determined. MRFIT showed relative risk of ESRD to be 1.7 in men for 
every 16 mm Hg increase in SBP. Baseline SBP of > 14O mm Hg were 
associated with a 5-6 fold greater risk for ESRD compared with SBP  
below 117 mm Hg . 
PATHOPHYSIOLOGY OF HYPERTENSION 
ENVIRONMENTAL AND PSYCOSOCIAL STRESS 
                                     Observation   of    people   who   move   from   
stable   rural traditional  societies to unstable urban environment showed 
increase in BP over the lifespan 14 . Westernized  people with low socio 
economic status have higher BP 15. Type A  or  coronary  prone  behavior  
pattern  is associated with increased BP and risk   of  Coronary  heart   
disease16.   Anger  arousing  experiments have long been known  to  raise  
BP  and increase vasoconstriction17,18. Other psychological factors related   
to   increase   in   BP   are   power   motivation (desire to dominate others), 
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depression19,20, hopelessness and  pessimism . The effect of persistent 
hopelessness was equivalent  to  that  of   smoking  2.5  packs of cigarettes 
daily 21,22 .  The stress buffers like social support, aerobic exercises and 
stress reduction interventions like bio feedback ,  relaxation  training  and  
cognitive  behavioral  therapies  have been shown to lower B.P. with mixed 
success 23.  
RENIN-ANGIOTENSIN SYSTEM (RAS) 
                     In humans, rennin is coded for by a single gene in 
chromosome-1.  It is secreted by juxta- glomerular  cells in response to 
decrease perfusion. The renin converts angiotensinogen to angiotensin I 
which is converted to angiotensin II by ACE. Angiotensin II is thought to 
be responsible for most of the physiologic and pathophysiologic effects of 
RAS.  Evidences   are accumulating that ACE  polymorphism due to 
insertion  or deletion may be responsible at least  a part to the pathology of 
essential hypertension24,25,26.                                                 
ALDOSTERONE AND MINERALOCORTICOIDS.                                                        
                     Apart from the physiological role  in retaining Na + and 
excreting K + in epithelial cell, Aldosterone has other less explored 
functions like vasoconstriction through its direct action on vascular smooth 
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muscle, in brain to stimulate salt appetite and direct action on cardiac 
myocytes which may contribute to essential hypertension.  
INSULIN RESISTANCE AND HYPERINSULINEMIA.    
  Though the relation between hyperinsulinemia and hypertension is 
well established the mechanisms by which it rises the BP remains doubtful 
and complex.  The possible mechanisms include. 
1. Insulin mediated salt retention 27,28. 
2. Insulin activation of sympathetic nervous system 29,30. 
3. Proliferative effects of insulin31. 
4. Non enzymatic glycation of interstitial tissues in arterial walls 32. 
5. Insulin induced endothelial dysfunction leading to arterial stiffness. 
REMODELLING OF RESISTANT ARTERIES IN HYPERTENSION. 
  Abnormalities of endothelial cells, smooth muscle cells, adhesion 
molecules and extra cellular matrix in vasculature may contribute to 
structural, mechanical and functional changes that reduce lumen diameter 
of small arteries (400 – 100 micron).There are two types of remodeling. 
1. Eutrophic remodeling in which the cross sectional area of lumen is 
maintained 
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2. Hypertrophic remodeling in which the cross sectional area of lumen 
is increased. 
Of these the   Eutrophic remodeling occurs in essential hypertension. 
ENDOTHELIUM IN HYPERTENSION 
  The two major endothelium derived vasoactive substances are 
Nitric oxide (NO) and Endothelin (ET).Nitric oxide is released from 
endothelium in response to shear stress and exerts vasodilating and 
antiproliferative effects on smooth muscle cells. It also inhibits the 
thrombocyte aggregation and leucocyte adhesion. The whole body Nitric 
oxide production in patients with essential hypertension is diminished 
under basal conditions33,34. Oxidative stress plays an important role in the 
pathogenesis of hypertension by oxidation of Nitric oxide to peroxynimine 
by superoxide anion thereby effectively reducing the bioavailability of 
Nitric oxide 35,36.   
    Endothelin exerts its major vascular effects, vasoconstriction and 
cell proliferation  through  ET  A receptors on vascular smooth muscle 
cells. In contrast ET B receptor mediate vasodilation via release of NO and 
prostacyclin. Apart from the  effects  on  blood  vessels  it  also causes 
sodium retention and Renin release in kidneys ,  Aldosterone  release from 
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adrenals and hypertrophy and fibrosis of heart musculature.These effects 
may contribute to essential hypertension in human37,38,39. 
NATRIURETIC AND VASODILATORY PEPTIDES 
         The   natriuretic   peptides   including   ANP  ,  BNP , CNP ,  DNP  
and urodilantin   performs  multiple  functions  like  natriuresis  ,   
vasodilation  ,   anti- proliferative  effects  , vascular  remodeling  and  
modulation of nor adrenergic and RAAS . In  addition  to these, the 
vasodilatory peptides like calcitonin gene related peptide   (CGRP)  ,  
substance   P  and  Adrenomedullin   regulates   cardiovascular function  in  
normal state  and  in  hypertension. 
THE KALLIKREIN – KININ SYSTEM 
  The kininogenic enzymes act on kininogen to form kinins. The 
kinins act via  two  receptors . The B1 receptor mediates inflammation , 
pain and fibrosis, the  B2  receptor  mediates  the  depressor ,  natriuretic , 
antitrophic and fibrinolytic functions    via    mediators   like   Eicasanoids  
,   EDHF   (  endothelium   derived hyperpolarizing factors ) , NO, t-PA etc. 
CONCEPT OF VASCULAR STIFFENING 
  A  decreased  distensibility  of aorta and other large arteries or the 
loss of  the  windkessel  function is known to be a cause for hypertension. 
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This vascular stiffening   develops   from   complex   interaction   between  
structural  and celluar elements  of   vessel  wall .   The  structural   
components   include   2    prominent scaffolding  proteins ,  collagen  and 
elastin . Dysregulation of the balance between the  production  and  
degradation  of  collagen and decreased  production of elastin which 
contribute to vascular stiffness 40. These vascular alterations  are influenced 
by   intrinsic   factors  41   like   hemodynamic   forces   and  extrinsic   
factors   like hormones,salt,glucose and lipids 42. 
  In  addition  to  the  structural  components  , cellular components 
also play a role  in  the  pathogenesis  of   vascular  stiffening .  They  are  
signals  from endothelial  cells  like  NO  and Endothelin -1 and the 
vascular smooth muscle tone The   Vascular  smooth  muscle   tone  is  
modified  by mechanostimulation and by paracrine mediators like 
Angiotensin II , ET -1 , oxidative stress and nitric oxide43       
       DEFININIG HYPERTENSION 
   The   multiple  risk  factor intervention tria  (MRFIT ) 
demonstrated a continous  and  graded  influence  of   both  systolic and 
diastolic blood pressure of coronary heart disease mortality extending down 
to systolic blood pressures of 120 mm Hg. Therefore from an 
epidemiologic  perspective ,there is no obvious level of blood pressure that 
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defines hypertension. Clinically “Hypertension  may be defined as  that  
level  of  Blood  pressure at which the institution of therapy reduces Blood 
pressure   related   morbidity   and   mortality ” .   The   JNC   VII classifies 
hypertension as follows  
 
      CLINICAL DISORDERS OF HYPERTENSION 
   Depending  upon  the   methods  of  patient ascertainment, 80-95% 
of hypertensive  patients   are diagnosed to have “Essential Hypertension ( 
also called as  Primary  or  Idiopathic  Hypertension  ) .  In  the  remaining  
5-20 % , a specific underlying   disorder   causing  the  elevation   of  blood 
pressure can be identified. These group is called “ SECONDARY 
HYPERTENSION”.Essential Hypertension tends  to  be  familial and is 
     SBP (mm Hg )     DBP ( mm Hg)  
Normal  <120 and <80 
Pre HT 120-139 Or 80-89 
Stage 1 140-159 Or 90-99 
Stage 2 >/ 160 Or >/100 
ISH >/140 And  <90 
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likely to be the consequences of an interaction between environmental and 
genetic factors. 
PATHOLOGIC CONSEQUENCES OF HYPERTENSION 
              Hypertension   is   a  risk  factor  for  atherosclerosis .  It is an 
independent predisposing  factor  for  heart  failure,coronary artery disease, 
stroke, renal disease and peripheral arterial disease. 
HEART 
  Hypertensive   heart   disease  is the result of structural and 
functional adaptations  of heart leading to left ventricular hypertrophy, 
diastoloic dysfunction, congestive  heart failure, coronary heart disease, 
microvascular disease and cardiac arrythmias. 
BRAIN 
    Hypertension  is   an   important   risk  factor for brain infarction 
and haemorrhage . Hypertension is also associated with an impaired 
cognition in aging population .  In  malignant   hypertension   there  is  loss 
of cerebral auto regulation leading  to  hyperperfusion causing 
encephalopathy which may progress to stupor , coma, seizures and death 
within hours if left untreated. 
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KIDNEY                                                                                                                              
                  Hypertension is an important risk factor for renal injury and 
ESRD. The      atherosclerotic  hypertension  related  vascular  lesion  in 
kidney primary affect the pre  glomerular  arterioles  ,   resulting  in  
ischemic  changes in glomeruli and post glomerular  structures  .   The  
injury   may   also   be   due  to  direct damage to the glomerular  capillaries   
due   to   hyperperfusion  .   The    pathology   progress   to 
glomerulosclerosis  and  eventually  to gradual atrophy of tubules. The 
renal lesion associated  with  malignant   hypertension  consists of fibrinoid 
necrosis of afferent arterioles and sometimes the necrosis of glomerular 
tuft. 
PERIPHERAL ARTERIES 
                   In  addition  to  contributing to the pathogenesis of 
hypertension, blood vessels   may  be  a   target  organ  for hypertension. 
Intermittent claudication is the classical symptom of peripheral artery 
disease.Retinopathy is also common.  
PATIENT APPROACH & EVALUATION 
        The initial assessment include a complete history to confirm a 
diagnosis and   to   screen   for   cardiovascular  risk   factors  to rule out 
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secondary causes of hypertension .  Most   of   the   hypertensive   patients  
have  no  specific symptoms referable  to  elevated  BP .  Headache 
generally occurs only in patients with severe hypertension .  
Characteristically  a  hypertensive  headache  occurs in the morning and   is   
localized  to   occipital  region .  Other  non  specific  symptoms related to 
elevated BP include dizziness, palpitation , easy fatiguability and 
impotence. 
MEASUREMENT OF BP 
  Before   taking  the  BP measurement , the individual should be 
seated quietly for 5 min in a private quiet setting with comfortable room 
temperature. The centre   of   the  cuff  should  be  at the heart level and the 
width of the bladder cuff should  be  equal  to atleast 40% of the arm 
circumference. The rate of deflation of the  cuff is  2 mm  Hg /sec. systolic 
blood pressure is the first of atleast two regular “ tapping  “ Korotkoff 
sounds and diastolic blood pressure is the point at which the last   regular   
Korotkoff   sound   is   heard  .   In   current   practice, a diagnosis of 
hypertension is generally based on seated office measurement. 
  Currently   available  ambulatory  monitors  are  fully  automated , 
use  oscillometric  technique  and  typically  are   programmed  to  take BP 
every  15-30 mins.  Ambulatory monitoring of BP is not routinely used and  
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reserved for patients in whom hypertension is suspected.TheJNC VII  has 
also recommended  ambulatory   monitoring  for  treatment  of  resistant, 
symptomatic hypotension , autonomic failure and episodic hypertension. 
PHYSICAL EXAMINATION 
  Body habitus include weight and height should be noted. At the 
initial examination BP should be measured in both arms and preferably in 
supine, sitting and standing positions. In hypertension diagnosed before the 
age of 30 years, lower limb BP should be checked. All the peripheral pulses 
should be examined for rate,  rhythm , volume and character. Heart rate 
should be  recorded  .   Neck  should  be palpated for thyroid gland. 
Fundoscopic examination should be done. Auscultation for bruit over 
carotids,femorals and renal arteries is done. cardiac  auscultation   for loud  
S2  and  S4  Gallop is done. Palpation of the precordium is done for a 
heaving apical impulse. 
LABORATORY TESTING  
Basic laboratory testing for initial evalution 
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      RENAL ELECTROLYTES METABOLIC OTHERS 
Urine microscopy 
Urine albumin  
BUN 
Ser.creatinine 
Ser.sodiun 
Ser.potassium 
Ser.calcium 
FBS 
Lipid profile 
Hematocrit 
ECG 
 
              The aim  of   anti - hypertensive management by various means is 
to bring down and to maintain the BP below 140/90 mmHg.In diabetic 
patients the BP goal is 130/80 mmHg and in nephropathy patients it 
is125/75 mmHg. 
DYSLIPIDEMIA 
         Dyslipidemia  is  the  most prevalent and important modifiable risk 
factor for atherosclerosis  .  Proper treatment reduces the risk for cardiac 
death, non fatal MI, stroke,  and  peripheral  vascular  disease by 25 – 50 
%. Despite these benefits only 20 % of adults meet national guidelines for 
cholesterol control. 
   Dyslipidemia is defined as abnormal lipid status. Common 
lipid abnormalities  include  elevated  total cholesterol, LDL cholesterol, 
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lipoprotein ( a) and  triglycerides ,  low  level  of  HDL  cholesterol and a 
preponderance of  small  density  LDL particles. These abnormalities occur 
alone or in combination. 
PREVALANCE, RISK AND SCREENING 
  Approximately 50%  of US  adults have an elevated  total 
cholesterol. In a vast majority of the patients with atherosclerotic vascular 
disease there is some form  of  dyslipidemia  even though their total 
cholesterol is normal. Elevated total Cholesterol ,   LDL c  and  low HDL c  
levels are major modifiable risk factors for coronary heart disease and other 
forms of  atherosclerotic vascular disease. ATP III recommends a  routiene  
lipoprotein analysis for all adults aged 20 years. screening should   be   
repeated   every  5   years  .   Since  dyslipidemia is  an  asymptomatic 
condition, early recognition and treatment improves prognosis. 
EFFECT OF THERAPY 
  Several  large  randomized ,  placebo controlled trials of statin 
therapy have shown reduction in cardio vascular  morbidity  and mortality. 
A meta-analysis of  more  than  330  interventional   trials  has  shown  that   
for  every   1 %  total cholesterol, mortality is reduced by 1.5 % and for 
each 1 % reduction in LDL c and for each 1 % increase in HDL c, the risk 
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for cardiovascular events is reduced  by  2 % and 3 %  respectively 44.A 
number of studies with serial  angiography  also show that the increase in 
stenosis was 1-3 % less per year in aggressively treated patients than in 
placebo. The lower level of LDL c maximum benefit extends  to  as low as 
50 -70 mg/dl for high risk patients. 
LDL   CHOLESTEROL GOALS  
  The  LDLc  goals  are   individualized  depending  on their  CHD  
risk                                                                                                                                 
MAJOR RISK FACTORS THAT MODIFY LDL GOALS 45 
                             The first step in estimating the LDL c goal is counting 
the number of risk factors 
Cigarette smoking Age (male > 45 yrs ; women > 55 yrs)
Hypertension   Obesity ( BMI > 30 kg/m2 ) 
HDL  c ( <40 mg/dl) Physical inactivity 
 Diabetes mellitus Atherogenic diet 
Family history of premature CHD Emerging risks 
 
  The next step in calculation of the 10 year risk of coronary heart 
disease  using  the  Framingham  heart study risk score. Based on these,  
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individuals are classified in 5 groups and their LDL c goals are set. 
VERY HIGH RISK GROUP-     LDL c goal < 70 mg % 46 
             10 year risk for major coronary event > 20 % 
   Established CHD 
   CHD equivalents 
   Diabetes mellitus 
   Multiple cardiovascular risk factors 
HIGH RISK  -   LDL c goal < 100 mg % ,optional goal < 70 mg %  
   Coronary heart disease  
   Coronary heart disease risk equivalents 
   10 year risk > 20 % 
   > 2 risk factors 
MODERATELY HIGH RISK -LDLc goal < 130mg%,optional< 100 mg % 
   10 year risk  10- 20 % 
   > 2 risk factors   
MODERATE RISK -LDL c goal < 130 mg % 
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   10 year risk < 10 % 
   >  2 risk factors 
LOWER RISK- LDL c goal < 160 mg %   
   0-1   risk factors 
NON HDL CHOLESTEROL 47 
   Non  –  HDL c  is  calculated   by   subtracting   HDL c  from 
TC.The primary   goal  of  therapy  for  persons  with  dyslipedimia  is 
LDL-c  lowering . A secondary goal of non -HDL c is set by ATP III 
guidelines. 
High / Very high risk - < 130 mg/dl.(optional < 100 mg / dl ) 
 Moderately high risk - < 160 mg/dl.(optional < 130 mg / dl ) 
Moderate risk - < 160 mg / dl 
Low risk - < 190 mg / dl 
TREATMENT OF DYSLIPIDEMIA 
 THEREPEUTIC LIFE STYLE CHANGE 48,49,50.  
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                   This   includes  Diet ,  physical activity , weight reduction and 
smoking cessation . In many individuals this could reduce total cholesterol 
by < 10%. 
DRUGS 
DRUGS MECHANISM LIPID LOWERING 
Statins HMG CoA reductase inhibitors LDL c : 18 – 55 % 
HDL c : 5 – 15 % 
TG       : 7 – 30 % 
Ezetimibe Decrease cholesterol absorption LDL c : 18 – 20 % 
HDL c : 1 – 5 % 
TG       : 5 – 11 % 
Niacin Decrease production and release  
 of VLDL 
LDL c : 5 – 25 % 
HDL c : 15 – 35 % 
TG       : 20 – 50 % 
Bile acid 
sequesterants 
Prevents enterohepatic circulation
 of BA 
LDL c : 15 – 30 % 
HDL c : 3 – 5 % 
TG       : unaffected 
Fibrates Increase LPL activity LDL c : 5 – 20 % 
HDL c : 10 – 35 % 
TG       : 20 – 50 % 
Omega 3  
fatty acids 
DHA and EPA reduce  
VLDL production 
LDL c : 44 % incr 
HDL c : 9 % 
TG       : 45 % 
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DYSLIPIDEMIA AND HYPERTENSION -    
THE METABOLIC SYNDROME                                                                                     
                 It consists of a constellation of metabolic abnormalities that 
confer increased risk of cardio vascular disease and diabetes mellitus. 
NCEP: ATP III, 2001 CRITERIA FOR METABOLIC SYNDROME 
  Three or more of the following : 
1.central obesity:waist circumference for male>102 cm and female >88 cm. 
2.Hypertriglyceridemia: Triglycerides >150 mg/dl or on  medication 
3.Low HDL c : < 40 mg/dl for males and < 50 mg/dl for females or on 
medication. 
4.Hypertension: Blood pressure > 130 mm Hg Systolic  or  > 85 mmHg 
diastolic  
5.Fasting plasma glucose: >= 100 mg /dl or specific medication 
                  Detailed   analysis of the components of Metabolic syndrome 
have been done  and   the  influence  of  one  component  on   the  other 
have  been found out.  Various cross sectional studies have suggested a link 
between  abnormal lipids and hypertension. A few studies have 
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prospectively examined the relationship between plasma lipids and further 
development of hypertension. Small trials have looked at the effect of lipid 
lowering on BP. 
ROLE OF LIPIDS IN THE PATHOGENESIS OF  HYPERTENSION. 
                    Dyslipidemia, causes endothelial damage and the loss of 
physiological vasomotor   activity   that  may  become  manifested   as  
increased blood  pressure. Atherogenic lipid abnormalities cause 
endothelial dysfunction 51 .  A  dysfunctional endothelium through impaired  
nitric  oxide  production and activity and alterations in Endothelin – 1  and  
Endothelin –A & B  receptor expression52, cannot respond to intra – 
vascular  conditions to dilate as needed. This vaso- dysregulation 
eventually leads to increased resting B.P. 
     Nickenig and Harrison53,54 have linked lipids and hypertension via a 
mechanism of angiotensin-І overexpression.Lipid abnormalities and insulin 
resistance have been associated with sympathetic hyperfunction55. 
CLINICAL TRIALS IN PATIENTS WITH HT & DYSLIPIDEMIA 
ASCOT-LLA TRIAL56 
(Anglo –Scandinavian cardiac outcome Trial-Lipid lowering arm) 
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    10,305  men and women aged 40-79 years with hypertension and 
> 3  other risk factors and elevated cholesterol were randomized to 
Atorvastatin  10  mg or placebo. The primary end point : coronary heart 
disease, death or non fatal MI. 
            The Atorvastatin arm of the trial was stopped prematurely at 3.3 
years due to a significant 36% reduction in the primary end point. Benefits 
were apparent in the first  year .  Atorvastatin   also reduced fatal or non 
fatal stroke by 27%, total cardiovascular  events  by  21  %  and  total   
coronary  events  by  29 % . At 1 year Atorvastatin reduced total and LDL 
cholesterol by 24% and 35% respectively. 
ALLHAT – LLT 57 
(Anti hypertensive and lipid lowering treatment to prevent heart attack 
trial) 
        10,355 men and women aged >55 years with stage 1 and 2 
hypertension , > 2 additional coronary heart disease risk factor and LDL c 
120 -189 mg/dl ( 100 – 129 mg/dl in patients with CHD) were randomized 
to Pravastatin 40 mg/dl or usual care . Mean follow up for 4.8 years. 
     The   results   showed  Pravastatin   did  not  significantly  reduce all 
cause mortality ( primary end point ) or coronary Heart disease events ( 
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relative risk 0.91 p=0.16). Lack of  benefit  is  attributed to  substantial  ( 
30 %)   use of statins in the placebo  group , resulting in a modest 17 % 
differential in total cholesterol between Pravastatin and usual case groups. 
PHYSICIAN HEALTH STUDY 5 
                           It was a randomized double blind placebo contolled  trial  of  
aspirin and beta – carotene in the primary prevention of cardiovascular 
disease and cancer. The study consisted of 22 , 071 male physicians 
between the  age  40  –  84.  From  this 3110 men free of hypertension, 
CHD, and cancer were selected and TC and HDL c were measured and non 
– HDL and TC /HDL C ratio were calculated.  Over  mean follow up of 
14.1 years , 1019 men developed  hypertension .  In  cox  proportional 
hazards  model  adjusted  for  lifestyle  and  clinical risk factors, men in the 
highest quintile   of   TC ,   non – HDL c   and  TC /HDL-c   ratio  had  
increased  risks  of developing  hypertension of 23%, 39% and 54% 
respectively ,  compared  with  the participants in lowest quintile. 
  Furthermore mean in highest quintile of HDL-C had 32 % decreased risk 
of developing    hypertension   compared  with  those  in  the  lowest   
quintile . These prospective   cohort    data   suggest   that   dyslipidemia   
may   lead  to subsequent development of hypertension.  
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PLASMA LIPID PROFILE IN HYPERTENSIVE NIGERIANS 59 
                  Lipid profile studied in 150 hypertensive patients aged 30 – 
59 and 30 years   and   socio   economic status matched normotensive 
controls using standard laboratory   techniques  .  Of  the hypertensive 
patients 54% were females and 46% were males.Hypertensive patients 
heve significantly higher lipid profiles except for HDLc which did not 
showed any difference in the two groups. 
LIPID PROFILE OF HYPERTENSIVE PATIENTS IN SPAIN 60 
                   In “ San Cecilio  ”  university  hospital,Granada,Spain 50 
patients were studied.  They   were  divided  into  two groups.27 recently 
diagnosed hypertensive patients   and  23   healthy   controls   of   similar   
mean   age (45 years ) and BMI. Biochemical determinations were 
performed by  automated techniques.Student’s T test   and  Welch’s   test   
was   used   for  statistical analysis .Hypertensive patients showed   higher   
level of   creatinine , uric  acid , total cholesterol,triglycerides and chlorides 
than controls. 
LIPID PROFILE OF HYPERTENSIVE PATIENTS IN BANGLADESH 61 
                      This prospective study carried out in department of bio 
chemistry and molecular biology , university of Rajshahi , Bangaladesh. 60 
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human subjects of age ranging from 33 – 60 years were studied  . Among  
these 40 were hypertensive and 20   were   normotensive . Their   lipid   
profile results were collected and analyzed statistically. The total 
cholesterol  ( 241.25 vs 182.14 )  ,   triglycerides  ( 184.77 vs 142.73 )   and   
LDL  c   ( 154.32  vs  105.73 ) were significantly higher and HDL c ( 32.91 
vs 42.88 ) was significantly low among hypertensive patients. 
MULTICENTRIC HYPERTENSIVE POPULATION STUDY IN UAE 62 
                                   Study  conducted  in 162 hypertensive and 112 normotensive  
 matched  for  age ,   gender ,   &  ethnicity  to  determine ET-1 , NO, lipid  
profile. Levels of VLDL and TG were significantly higher ( P < 0.01 )  in  
hypertensive. In contrast total cholesterol ( P < 0.01 ) and LDL  c ( P < 
0.001 )  were  lower  among hypertensive. ET-1 and  NO were significantly 
higher in hypertensive.               
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MATERIALS AND METHODS 
              Patients who are diagnosed as hypertensive in medical OP 
department, ward   and   hypertension   clinic  of   Kilpauk  medical  
college  govt hospital were taken.Study population included patients 
belonging to urban and semi urban city of Chennai. Study period is from   
January 2009   to October 2009.                             
  The Study design is Cross sectional study with cases and controls. 
The study group included 
• Newly detected hypertensive patients of age group between 31-75 yrs. 
• Control group is non-hypertensive patients of same age group who 
attended medical OPD for minor illnesses. 
Following group were excluded from the study 
• Patients who are already known hypertensive and on drugs. 
• Patients with secondary hypertension. 
• Newly diagnosed hypertensive patients with one or more complications 
like CVA, IHD, nephropathy and retinopathy at presentation. 
• Hypertensive patients who are alcoholic. 
• Hypertensive diabetic patients. 
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                 The participants  were  explained  about the study and informed 
consent was  obtained.  Then  they   were  interviewed  and  analyzed for 
exclusion criteria. Cases  which meet both the inclusion criteria and did not 
have any of the exclusion criteria were selected to participate in the study. 
                107  such  cases  60  controls were included in the study. Detailed 
history regarding patient’s education, occupation , family income, daily 
physical activities, smoking, alcohol intake and family history  of  
hypertension  were asked.The socio economic  status   of   the   patient   
was   determined   using   “  Modified    (2007) Kuppuswamy   scale ”.   
Participants   with   daily   physical   activity  of  ≤ 2 MET (Metabolic 
Equivalent of Task) were considered as sedentary. Those who smoke ≥ 5 
cigarettes ⁄ day were considered as smokers. 
             Waist circumference was measured in a horizontal plane at the 
level of the narrowest part between the costal margin and the iliac   crest .  
Hip   circumference was measured at  the   largest  protrusion  of   the  
buttock with thin clothes without compressing the skin. Body mass index 
(BMI) was calculated using the formula  
               BMI = Weight in kg / (Height in meter)² 
The  waist  hip  ratio  was  also calculated. Participants with BMI ≥ 25 
kg/m², waist circumference   ≥   88 cm  in  females  and  ≥  102 cm in 
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males and WHR ≥ 0.85 in females and ≥ 0.90 in males were considered 
obese.Blood  pressure  was measured in  the  right  arm  in  patient in 
sitting posture. It was measured after 30 min of rest and  arm  supported  at  
heart  level .  They  were  also abstained from smoking and ingestion of 
caffeine within the previous 6 hrs .  Two  such  readings  were taken at 
least 24 hrs apart and the average of the two was taken. 
           5 ml of venous blood sample after an over night 12 hrs fasting was 
collected for investigation. A 2 hrs postprandial sample was also collected. 
The TC, TG  and HDL c  were  determined  using  enzymatic  calorimetric  
method . The LDL-c and VLDL-c were estimated using Friedeward 
formula. 
   LDL-c = TC − (HDL + VLDL) 
Participants with fasting blood sugar values from 100-125 mg/dl  and  
postprandial blood sugar values from 140-199 mg/dl were considered  to  
be pre-diabetic. Those who had TC ≥ 200 mg/dl or TG ≥ 150 mg/dl or LDL 
c ≥ 130 mg/dl  or  HDL c< 40 mg/dl  were  considered  as  dyslipidemic .  
Unpaired, double tailed student’s T test was  used  to  find  out  the  
significance  of  difference between the two means.The significance of 
difference in the percentage of dyslipidemia among each group was 
analysed using chi-square test. 
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RESULTS AND ANALYSIS 
• 107 patients with newly diagnosed hypertension from hypertension clinic 
were included in the study group.                     
• 60 non-hypertensive persons of same age group were included in the 
study as control. 
              To study the prevalence of dyslipidemia the hypertensive patients 
were compared with the normotensive group. 
                      To study the influence of various parameters on lipid profile, 
patients from   the  hypertensive  group  only  are selected. Patients who are 
positive for the parameters to  be  tested  act  as  cases  and   those who are 
negative act as controls. 
With the available data two type of analysis were done. 
• The mean values of Total cholesterol and other sub-groups of cholesterol 
are calculated  for  cases  and   controls  and  their differences were 
analyzed for statistical  significance . The  statistical  analysis  is  done 
using unpaired – T test, double tailed with unequal variance. 
•  The percentage of dyslipidemia prevalence for among cases and controls 
are calculated   and   compared.  The   percentage   prevalence   is  analyzed  
for statistical significance using Chi-square test. 
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  SUMMARY OF STATISTICS FOR CONTINUOUS VARIABLES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO         ITEMS      MEAN    MEDIAN    RANGE 
1 AGE 55.9159 58 30-75 
2 HEIGHT 157.907 158 138-174 
3 WEIGHT 67.4579 65 50-97 
4 BMI 27.2507 26.67276 19.8-40.4 
5 WAIST-CIRCUM 94.7664 95 78-116 
6 WHR 0.915415 0.918967 0.76-1.07 
7 SBP 162.710 160 130-200 
8 DBP 93.2897 90 10-140 
9 FBS 95.7196 96 72-123 
10 PPBS 126.121 126 93-190 
11 TC 196.804 191 150-283 
12 TG 197.312 180 58-495 
13 LDL 119.153 117 64-190 
14 HDL 37.935 38 24-53 
15 VLDL 40.0617 36.8 12-99 
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TABLE-1: MEAN LIPID VALUES: CASES VS CONTROLS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERPRETATION 
               The total cholesterol, triglycerides, LDL-c and HDL-c are 
significantly higher in hypertensive patients (cases) when compared with 
non-hypertensive patients (control). 
 
 
 
 
LIPID       ‛ N ’ MEAN     SE ‛ P ’ 
CASES 107 197 2.67 
TC 
CONTROL 60 166 2.77 
< 0.0001 
SIGNIFICANT 
     
CASES 107 197 7.03 
TG 
CONTROL 60 120 5.40 
< 0.0001 
SIGNIFICANT 
     
CASES 107 119 2.45 
LDL 
CONTROL 60 98.4 2.74 
< 0.0001 
SIGNIFICANT 
     
CASES 107 37.9 0.63 
HDL 
CONTROL 60 42.3 0.98 
< 0.0001 
SIGNIFICANT 
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TABLE-2: PERCENTAGE OF DYSLIPIDEMIA: 
CASES VS CONTROLS                        
 
INTERPRETATION: 
              In our study, dyslipidemia is defined as TC ≥ 200 mg/dl, TG ≥ 150 
mg/dl,LDL ≥ 130 mg/dl and HDL < 40 mg/dl. Cases have significantly 
higher percentage of dyslipidemics when compared with control. 
 
LIPID           ‛ N ’ PERCENT ‛ P ’ 
CASES 107 43.92 
TC 
CONTROL 60 5 
< 0.0001 
SIGNIFICANT 
     
CASES 107 84.11 
TG 
CONTROL 60 20 
< 0.0001 
SIGNIFICANT 
     
CASES 107 28.03 
LDL 
CONTROL 60 5 
0.0003 
SIGNIFICANT 
     
CASES 107 53.27 
HDL 
CONTROL 60 30 
0.005 
SIGNIFICANT 
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TABLE-3: MEAN LIPID VALUES IN DIFFERENT AGE-GROUPS  
LIPID    ‛ N ’ MEAN     SE ‛ P ’ 
YRS (31-45) 25 189 4.08 
TC 
YRS (61-75) 47 203 4.38 
0.049 
SIGNIFICANT 
     
YRS (31-45) 25 182 12.88 
TG 
YRS (46-60) 35 217 16.73 
0.12 
IN-SIGNIFICANT
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I
N
TERPRETATION 
        Three age groups were formed among the hypertensive patients. 
Group-І: 31-45yrs, group-Π: 46-60yrs and group-Ш: 61-75yrs. The total 
cholesterol is significantly high among hypertensive patients of group-Ш 
when compared with group-І. 
 
 
 
 
TABLE-4: PERCENTAGE OF DYSLIPIDEMIA IN AGE-GROUPS 
YRS (46-60) 35 111 4.77 
LDL 
YRS (61-75) 47 127 3.44 
0.0072 
SIGNIFICANT 
     
YRS (31-45) 25 38.4 1.23 
HDL 
YRS (61-75) 47 37.6 0.97 
0.60 
IN-SIGNIFICANT
     
LIPID   ‛ N ’ PERCENTAGE ‛ P ’ 
YRS ( 31-45 ) 25 20.00 
TC 
YRS ( 61-75 ) 47 53.19 
0.0151 
SIGNIFICANT 
     
TG YRS ( 46-60 ) 35 82.85 0.9637 
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         INTERPRETATION 
              Significant percentage of dyslipidemics is present in group-Ш 
with respect to total cholesterol and triglycerides when compared with 
groups with lowest lipid values. 
 
 
 
 
TABLE-5: MEAN LIPID VALUES: MALES VS FEMALES 
YRS ( 61-75 ) 47 85.10 IN-SIGNIFICANT 
     
YRS ( 31-45 ) 25 20.00 
LDL 
YRS ( 61-75) 47 36.17 
0.2459 
IN-SIGNIFICANT 
     
YRS ( 31-45 ) 25 52.00 
HDL 
YRS ( 46-60 ) 35 54.28 
0.9861 
IN-SIGNIFICANT 
     
  
38 
 
 
        INTERPRETATION 
                Hypertensive females have significantly higher HDL levels when 
compared with hypertensive males. 
 
 
 
TABLE-6: PERCENTAGE OF DYSLIPIDEMIA: MALES VS 
FEMALES. 
LIPID ‛ N ’ MEAN SE ‛ P ’ 
MALE 58 198 3.62 
TC 
FEMALE 49 195 3.96 
0.50 
IN-SIGNIFICANT 
     
MALE 58 201 8.29 
TG 
FEMALE 49 192 11.88 
0.52 
IN-SIGNIFICANT 
     
MALE 58 121 3.11 
LDL 
FEMALE 46 116 3.89 
0.31 
IN-SIGNIFICANT 
     
MALE 58 36.4 0.78 
HDL 
FEMALE 49 39.7 0.96 
0.0084 
SIGNIFICANT 
     
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
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         INTERPRETATION 
 Significant percentages of female hypertensive patients have HDL values 
> 40 mg/dl 
 
 
 
 
TABLE-7: MEAN LIPID VALUES: SMOKERS VS NON-SMOKERS 
MALE 58 50.00 
TC 
FEMALE 49 38.77 
0.2448 
IN-SIGNIFICANT 
     
MALE 58 87.93 
TG 
FEMALE 49 79.59 
0.2398 
IN-SIGNIFICANT 
     
MALE 58 34.48 
LDL 
FEMALE 49 20.40 
0.1063 
IN-SIGNIFICANT 
     
MALE 58 63.79 
HDL 
FEMALE 49 40.08 
0.0176 
SIGNIFICANT 
     
LIPID ‛ N ’ MEAN SE ‛ P ’ 
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IINTERPRETATION 
 Hypertensive smokers have significantly higher TC, TG and HDL values 
when compared with hypertensive non-smoker males. 
 
 
TABLE-8: PERCENTAGE OF DYSLIPIDEMIA          
   SMOKERS VS NON-SMOKERS. 
SMOKER 22 215 6.49 
0.00014 
SIGNIFICANT TC 
NON-
SMOKER 36 188 3.32  
      
SMOKER 22 233 16.98 
TG NON-
SMOKER 36 182 6.77 
0.0019 
SIGNIFICANT 
      
SMOKER 22 129 6.89 
LDL NON-
SMOKER 36 117 2.55 
0.07327 
IN-SIGNIFICANT 
      
SMOKER 22 39.3 1.33 
HDL NON-
SMOKER 36 34.7 0.85 
0.00304 
SIGNIFICANT 
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INTERPRETATION 
           Hypertensive smokers have significantly high percentage of patients 
with TC in dyslipidemic range (TC ≥ 200 mg/dl) when compared with 
hypertensive non-smokers. 
 
 
 
TABLE-9: MEAN LIPID VALUES: BODY MASS INDEX (BMI) 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
SMOKER 22 69.56 
TC 
NON-SMOKE 36 34.28 
0.0085 
SIGNIFICANT 
     
SMOKER 22 95.65 
TG 
NON-SMOKE 36 85.71 
0.2236 
IN-SIGNIFICANT 
     
SMOKER 22 39.13 
LDL 
NON-SMOKE 36 28.57 
0.4018 
IN-SIGNIFICANT 
     
SMOKER 22 56.52 
HDL 
NON-SMOKE 36 68.57 
0.35 
IN-SIGNIFICANT 
     
LIPID ‛ N ’ MEAN SE ‛ P ’ 
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INTERPRETATION 
          Hypertensive patients with BMI ≥ 25 kg/m² are considered obese and 
< 25 kg/m² as non-obese. Obese patients showed significantly higher 
values of all lipid parameters. 
 
 
 
 
TABLE-10: PERCENTAGE OF DYSLIPIDEMIA: BODY-MASS INDEX 
OBESE 74 205 3.12 
TC 
NON-OBESE 33 177 3.09 
< 0.0001 
SIGNIFICANT 
     
OBESE 74 209 9.42 
TG 
NON-OBESE 33 171 6.72 
0.011 
SIGNIFICANT 
     
OBESE 74 124 3.24 
LDL 
NON-OBESE 33 109 2.40 
0.0035 
SIGNIFICANT 
     
OBESE 74 39.6 0.68 
HDL 
NON-OBESE 33 34.1 1.08 
< 0.0001 
SIGNIFICANT 
     
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
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N 
 
 
INTERPRETATION 
         Hypertensive patients with BMI ≥ 25 kg/m² have significantly higher 
percentage of TC, LDL and HDL in dyslipidemic range when compared 
with hypertensive patients with BMI < 25 kg/m². 
 
 
 
 
       TABLE-11: MEAN LIPID VALUES: WAIST - CIRCUMFERENCE 
OBESE 74 58.10 
TC 
NON-OBESE 33 12.12 
< 0.0001 
SIGNIFICANT 
     
OBESE 74 87.83 
TG 
NON-OBESE 33 75.75 
0.1149 
IN-SIGNIFICANT 
     
OBESE 74 36.48 
LDL 
NON-OBESE 33 9.09 
0.0036 
SIGNIFICANT 
     
OBESE 74 44.59 
HDL 
NON-OBESE 33 72.72 
0.007 
SIGNIFICANT 
     
LIPID ‛ N ’ MEAN   SE ‛ P ’ 
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        INTERPRETATION 
       Hypertensive patients with waist circumference ≥ 102 cm for males 
and ≥ 88 cm for females were considered obese. Obese patients have 
significantly high TC, TG and LDL values when compared with non-obese 
patients. 
 
 
TABLE-12: PERCENTAGE OF DYSLIPIDEMIA: 
OBESE 48 208 3.95 
TC 
NON-OBESE59 188 3.20 
0.00015 
SIGNIFICANT 
     
OBESE 48 215 12.48 
TG 
NON-OBESE59 183 7.30 
0.024 
SIGNIFICANT 
     
OBESE 48 126 4.34 
LDL 
NON-OBESE59 114 2.55 
0.019 
SIGNIFICANT 
     
OBESE 48 39.2 0.75 
HDL 
NON-OBESE59 36.9 0.94 
0.06218 
IN-SIGNIFICANT 
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  WAIST-CIRCUMFERENCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
NTERPRETATION 
           Hypertensive patients who are obese with respect to waist 
circumference have significantly higher percentage of patients with their 
TC and LDL in dyslipidemic range. 
 
 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
OBESE 48 64.58 
TC 
NON-OBESE 59 27.11 
< 0.0001 
SIGNIFICANT 
     
OBESE 48 87.50 
TG 
NON-OBESE 59 81.35 
0.3877 
IN-SIGNIFICANT 
     
OBESE 48 39.58 
LDL 
NON-OBESE 59 18.64 
0.0164 
SIGNIFICANT 
     
OBESE 48 45.83 
HDL 
NON-OBESE 59 59.32 
0.1642 
IN-SIGNIFICANT 
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TABLE-13: MEAN LIPID VALUES: WAIST-HIP RATIO (WHR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERPRETATION 
         Obesity when defined as waist hip ratio ≥ 0.85 in females and ≥ 0.90 
in males did not show any significant alterations in mean lipid values when 
compared with non-obese hypertensive patients. 
 
 
 
 
LIPID ‛ N ’ MEAN SE ‛ P ’ 
OBESE 80 198 2.97 
TC 
NON-OBESE 27 192 5.85 
0.28 
IN-SIGNIFICANT 
     
OBESE 80 204 8.93 
TG 
NON-OBESE 27 178 7.95 
0.119 
IN-SIGNIFICANT 
      
OBESE 80 119 2.78 
LDL 
NON-OBESE 27 120 5.27 
0.90 
IN-SIGNIFICANT 
     
OBESE 80 38.3 0.70 
HDL 
NON-OBESE 27 36.8 1.36 
0.29 
IN-SIGNIFICANT 
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TABLE-14: PERCENTAGE OF DYSLIPIDEMIA: WAIST-HIP RATIO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       INTERPRETATION 
             Hypertensive patients with waist-hip ratio in obese range did not 
show any significant high percentage of dyslipidemia. 
 
 
 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
OBESE 80 47.50 0.1996 
TC 
NON-OBESE 27 33.33 IN-SIGNIFICANT 
     
OBESE 80 87.50 0.0989 
TG 
NON-OBESE 27 74.07 IN-SIGNIFICANT 
     
OBESE 80 28.75 0.51 
LDL 
NON-OBESE 27 22.22 IN-SIGNIFICANT 
     
OBESE 80 51.25 0.4713 
HDL 
NON-OBESE 27 59.25 IN-SIGNIFICANT 
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TABLE-15:  MEAN LIPID VALUES: 
 SEDENTARY VS NON-SEDENTARY 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
        INTERPRETATION 
                Hypertensive sedentary patients have significantly higher values 
of all lipids when compared with hypertensive non-sedentary patients 
 
 
 
 
 
LIPID ‛ N ’ MEAN SE ‛ P ’ 
SEDENTARY 58 208 3.83 
TC 
NON-SEDENT 49 183 2.59 
< 0.0001 
SIGNIFICANT 
     
SEDENTARY 58 212 11.75 
TG 
NON-SEDENT 49 180 5.74 
0.022 
SIGNIFICANT 
     
SEDENTARY 58 125 4.07 
LDL 
NON-SEDENT 49 112 1.98 
0.00924 
SIGNIFICANT 
     
SEDENTARY 58 40.1 0.79 
HDL 
NON-SEDENT 49 35.3 0.87 
< 0.0001 
SIGNIFICANT 
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TABLE-16: PERCENTAGE OF DYSLIPIDEMIA: 
SEDENTARY VS NON-SEDENTARY 
 
       INTERPRETATION 
          Hypertensive sedentary patients have significantly higher percentage 
of individuals with TC and LDL, and significantly low percentage of 
individuals with HDL in dyslipidemic range. 
 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
SEDENTARY 58 62.06 < 0.0001 
TC 
NON-SEDENT 49 22.44 SIGNIFICANT 
     
SEDENTARY 58 87.93 0.3629 
TG 
NON-SEDENT 49 81.63 IN-SIGNIFICANT
     
SEDENTARY 58 37.93 0.0131 
LDL 
NON-SEDENT 49 16.32 SIGNIFICANT 
     
SEDENTARY 58 32.75 < 0.0001 
HDL 
NON-SEDENT 49 77.55 SIGNIFICANT 
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TABLE-17: MEAN LIPID VALUES: 
 SOCIOECONOMIC STATUS(SES) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERPRETATION 
         Hypertensive patients of SES 2&3 have significantly high mean TC, 
LDL and HDL values when compared with hypertensive patients of   SES 
4&5. 
 
 
 
LIPID ‛ N ’ MEAN SE ‛ P ’ 
SES 2 & 3 52 206 3.79 
TC 
SES 4 & 5 55 188 3.36 
0.00052 
SIGNIFICANT 
     
SES 2 & 3 52 206 11.85 
TG 
SES 4 & 5 55 189 7.79 
0.22 
IN-SIGNIFICANT 
     
SES 2 & 3 52 125 4.00 
LDL 
SES 4 & 5 55 114 2.74 
0.0186 
SIGNIFICANT 
     
SES 2 & 3 52 39.5 0.86 
HDL 
SES 4 & 5 55 36.4 0.86 
0.0132 
SIGNIFICANT 
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         TABLE-18: PERCENTAGE OF DYSLIPIDEMIA: 
 SOCIO-ECONOMIC STATUS 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERPRETATION 
          Hypertensive patients of SES 2&3 have significantly high percentage 
of individuals with TC and LDL in dyslipidemic range and significantly 
low percentage individuals with HDL in dyslipidemic range. 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
SES 2 & 3 52 61.53 
TC 
SES 4 & 5 55 27.27 
0.0004 
SIGNIFICANT 
     
SES 2 & 3 52 84.61 
TG 
SES 4 & 5 55 83.63 
0.8963 
IN-SIGNIFICANT 
     
SES 2 & 3 52 40.38 
LDL 
SES 4 & 5 55 16.36 
0.0057 
SIGNIFICANT 
     
SES 2 & 3 52 42.3 
HDL 
SES 4 & 5 55 63.63 
0.027 
SIGNIFICANT 
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TABLE-19: MEAN LIPID VALUES: STAGES OF HYPERTENSION 
 
INTERPRETATION 
          There is no significant difference in mean lipid values between 
patients in stage-1 and stage-2 hypertension. 
 
 
 
 
LIPID ‛ N ’ MEAN         SE ‛ P ’ 
STAGE - 1 32 191 4.02
TC 
STAGE - 2 75 199 3.37
0.19 
IN-SIGNIFICANT 
     
STAGE - 1 32 195 15.73 
TG STAGE - 2 75 198 7.54
0.86 
IN-SIGNIFICANT 
     
STAGE - 1 32 114 4.22
LDL 
STAGE - 2 75 121 2.98
0.153 
IN-SIGNIFICANT 
     
STAGE - 1 32 37.8 1.13
HDL 
STAGE - 2 75 38.0 0.76
0.899 
IN-SIGNIFICANT 
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TABLE-20: PERCENTAGE OF DYSLIPIDEMIA: 
 STAGES OF HYPERTENSION 
 
        INTERPRETATION 
            There is no significant difference in percentage prevalence of 
dyslipidemia among stage-1 and stage-2 hypertensives. 
 
 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
STAGE -1 32 43.75 
TC 
STAGE - 2 75 44.00 
1.00 
IN-SIGNIFICANT 
     
STAGE -1 32 84.37 
TG 
STAGE - 2 75 84.00 
0.9748 
IN-SIGNIFICANT 
     
STAGE -1 32 28.12 
LDL 
STAGE - 2 75 28.00 
1.00 
IN-SIGNIFICANT 
     
STAGE -1 32 50.00 
HDL 
STAGE - 2 75 54.66 
0.6596 
IN-SIGNIFICANT 
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TABLE-21:MEAN LIPID VALUES  
PRE-DIABETIC VS NON DIABETIC 
 
 
        INTERPRETATION 
          Hypertensive pre-diabetic patients have significantly high mean total 
cholesterol when compared with hypertensive non-diabetic patients. 
 
 
LIPID ‛ N ’ MEAN SE ‛ P ’ 
PRE-DIABET 35 206 4.61 
TC 
NON-DIABET 72 192 3.15 
0.0144 
SIGNIFICANT 
     
PRE-DIABET 35 208 14.56 
TG 
NON-DIABET 72 192 7.70 
0.31408 
IN-SIGNIFICAN
     
PRE-DIABET 35 125 4.83 
LDL 
NON-DIABET 72 116 2.74 
0.074 
IN-SIGNIFICAN
     
PRE-DIABET 35 38.8 1.15 
HDL 
NON-DIABET 72 37.5 0.76 
0.3543 
IN-SIGNIFICAN
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        TABLE-22:    PERCENTAGE OF DYSLIPIDEMIA: 
        PRE-DIABETIC VS NON-DIABETIC 
 
        INTERPRETATION 
          Significantly higher percentages of pre-diabetic hypertensive patients 
have their total cholesterol and LDL cholesterol in dyslipidemic range 
when compared with non-diabetic hypertensive patients. 
 
 
 
LIPID ‛ N ’ PERCENTAGE ‛ P ’ 
PRE-DIABET 35 62.85 
TC 
NON-DIABET 72 34.72 
0.0059 
SIGNIFICANT 
    
PRE-DIABET 35 82.85 
TG 
NON-DIABET 72 84.72 
0.8081 
IN-SIGNIFICANT
     
PRE-DIABET 35 42.85 
LDL 
NON-DIABET 72 20.83 
0.0173 
SIGNIFICANT 
    
PRE-DIABET 35 42.85 
HDL 
 NON-DIABET 72 58.33 
0.1323 
IN-SIGNIFICANT
    
  
56 
 
DISCUSSION 
PREVALENCE OF DYSLIPIDEMIA 
                On   analysis   of   the  lipid  profile   of 107 hypertensive patients 
and 60 normotensive  persons the mean TC values in cases and controls are 
197 mg/dl and 166 mg/dl  respectively.  The  mean  TG   values  are 197 
mg/dl and 120 mg/dl, the mean  LDL c  values  are  119  mg/dl  and  98.4 
mg/dl  .  All  these  differences are statistically significant with a ‛p’ value 
of < 0.0001 when analyzed with unpaired T test.The mean HDL (37.9 
mg/dl) in hypertensive is significantly lower (p <0.0001) than 
normotensive  (42.3 mg/dl). 
             About  43.92 %   of   hypertensive   has   high   TC  (i.e. ≥200 
mg/dl) when compared with  the  normotensives   (i.e. 5%).  High   TG  
(≥150 mg/dl)   is   found   in  84.11  %   of   the  hypertensive  population ,  
whereas  it  is   seen  only in 20% of  normotensives .  The  high LDL in the 
groups is 28.03% and 5%. The low HDL (<40 mg/dl) is seen in 53.27 %of 
hypertensive and 30% of normotensive. All these values are statistically 
significant when analyzed using Chi-square test.  
             The  results  are  similar  to the studies conducted in Nigeria by 
J.Idemudia E.Ugwuja  63  which  showed  a  significantly  elevated plasma 
TC, TG, LDL-c and HDL-c in hypertensive patients when compared with 
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normotensive patients. Studies   conducted  by  M.S . Saha,  N .K. Sana  
and  Ranajith   kumar  Shaha 64 in northern Bangladesh also showed a 
significantly high  TC ,  TG  and  LDL   values (TC-291.25 mg/dl vs. 
182.14 mg/dl, TG-184.77  mg/dl vs. 142.73 mg/dl and LDL-154.32 mg/dl 
vs. 105.73 mg/dl) and significantly lower HDL-c values (32.91 mg/dl vs . 
42.88  mg/dl )  in  hypertensive  patients  when  compared   with  
normotensive patients. Studies by Abdishakur Abdulla, Nico  Negelkerke  
65  in UAE   showed   a significantly  higher  level  of  VLDL  and TG 
among hypertensive patients but not TC and LDL levels. Studies  
conducted in  Spain by D.Rueda and A.Maldonado  66 showed a 
significantly high TC and TG than normotensive controls. 
 INFLUENCE OF AGE 
             The hypertensive patients included in our study were divided into 
three age groups  (31-45yrs, 46-60yrs, and 61-75yrs) and  the  mean lipid 
values of the group were compared. The TC were significantly higher in  
hypertensive of the group-Ш when  compared with  the  group-І  (mean TC 
203 mg/dl vs. 189 mg/dl,  p=0.049 ). The TG, LDL and HDL did not show 
any significant differences. On analyzing the percentage of dyslipidemia in 
each group ,  the  group - І  had  significantly  higher percentage of patients 
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with TC in dyslipidemic range (53.19% vs. 20%, p=0.0151) when 
compared with group-Ш 
INFLUENCE OF SEX 
   In our study hypertensive males have significantly lower mean HDL 
levels when   compared  with   hypertensive  females  (HDL  36.4  mg/dl  
vs . 39.7 mg/dl, p=0.0084). About 63.79% of males were in the  
dyslipidemic  HDL  range  ,  when compared  with  females  (40.08%) ,  
the  value  is  significant  (p=0.0084) .   Other cholesterols were higher in 
males but not significantly so. 
 Study conducted by S.A.Desai,  U . V .Mani ,  S. M . Deshmukh,  U.M 
.Iyer, A.K.Sen and R.P.Patel67 in Gujarat  showed  hypertensive males have 
significantly higher  TC   (200 mg/dl vs. 175.5 mg/dl) ,  TG  (176.5 mg/dl 
vs. 157.3 mg/dl)  and LDL  (128.1mg/dl  vs.  107.7 mg/dl )  levels. This 
favorable profile in females was probably  due  to  the  influence  of  
estrogen hormone. In contrast to our study this study showed a significantly 
higher HDL values in hypertensive males (40.7 mg/dl vs. 32.5 mg/dl). 
 In   Nigerian  study  by  J.Idemudia  and E.Ugwuja, the TC was 
significantly higher   in  hypertensive  females  (4.45 mmol/L vs .  4.86 
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mmol/L,  p=<0.05)  than hypertensive males. The other lipids including 
HDL-c were higher  in  females  but not in the significant range. 
     The study of northern Bangladesh showed higher TC, TG, LDL-c and 
low HDL-c levels in hypertensive males but the values were not 
significant. 
INFLUENCE OF SMOKING 
     The   mean  TC,  TG,  LDL and  HDL  values  in our study were higher 
in hypertensive smokers when compared with hypertensive non-smoker 
males. (Mean values: TC-215 mg/dl vs. 188 mg/dl, TG-233 mg/dl vs. 182 
mg/dl, LDL-129 mg/dl vs. 117 mg/dl and HDL- 39.3 mg/dl vs. 34.7 
mg/dl). Among  these  except LDL all values were statistically significant.  
The   percentage   of  dyslipidemia   is   higher among the smoker 
population with  respect  to all lipid parameters, but only the TC was 
significant. 
     In  the   study  conducted  by  Jaroslaw  Goldman and Marian Klinger68 
of Poland the hypertensive smokers  showed  higher  mean TC (6.23 
mmol/L vs. 5.57 mmol/L),  LDL-c  (3.80 mmol/L  vs .  3.76 mmol/L) ,  TG  
(2.53 mmol/L  vs . 1.60 mmol/L) and HDL-c (1.18 mmol/L vs. 1.13 
mmol/L).  Among  these  TC  and  TG were  statistically  significant .  The 
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results  were  exactly  similar to our study. The study by Mojgan Gharipour 
and Roya   Kelishadi  69  also  showed  a   significantly higher  TG  and  
LDL-c  values  (p=0.005 and 0.015 respectively) and insignificant but  high  
values  of TC (p=0.079) and insignificant but low value of HDL. A study 
by  S. A .Desai  and  U. V .Mani  in  Baroda  showed a significantly high 
TG and a insignificantly high TC values among smokers. Other  lipids  did  
not  show   much difference.  
   The proposed mechanisms by which smoking alters the lipid  profile  are  
70  
• Nicotine stimulates the release of adrenaline, leading to increased serum 
concentrations of  FFA. 
• FFA is a stimulant of hepatic secretion of VLDL and hence TG. 
• HDL-c varies inversely with VLDL-c in serum. 
• FFA also stimulates hepatic synthesis and secretion of cholesterol. 
• Smoking induces cytochrome p-450 system that degrades anti HT drugs71. 
INFLUENCE OF OBESITY 
Body Mass Index (BMI) 
      In our study obese patients when defined with BMI of ≥ 25 kg/m² 
showed significantly   high values of TC, TG, LDL and HDL ( p values 
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TC- < 0.0001, TG- 0.011 ,  LDL- 0.0035  and  HDL- < 0.0001). The 
percentage of dyslipidemia is also significantly higher among obese 
patients   with  respect to TC, LDL and HDL and insignificantly high with 
respect to TG. 
                 Study   by  Muhammad. S. Akthar  and  Sayeda.M.Ansar in 
Faisalabad72 pakistan showed TC  was significantly high among obese 
hypertensives and   LDL, TG  and  HDL  were   high   but  not  significant .  
The  study  by  S .A  .Desai  and      U.V.Mani in Baroda also showed the 
significantly high lipid  profile  of  TC ,  TG , LDL  and  HDL among  
obese  hypertensives.The high HDL among obese patients may be due to 
ample fruit intake and vegetable intake. 
Waist Circumference 
         Patients with obesity when defined as waist circumference of ≥ 88cm 
in females and ≥102cm in males showed significantly high values of TC 
(p=0.00015), TG (p=0.024), LDL(p=0.019) and high but insignificant 
(p=0.063) value of HDL. 
      The percentage of dyslipidemia was significantly high with respect to 
TC and LDL  and   insignificantly high with respect to TG and 
insignificantly low with respect to HDL. 
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Waist hip ratio (WHR) 
        Patients  with  obesity when defined by WHR ≥ 0.85 in females and     
≥ 0.9 in males showed high TC,  TG  and LDL values and low HDL values, 
but none of them were significant. The percentage  of  dyslipidemia p 
revalence also showed similar trend. 
INFLUENCE OF PHYSICAL ACTIVITY. 
          In our study hypertensive patients who were sedentary had 
significantly high TC, TG and LDL and significantly low HDL 
values.Study  by  Ignez Salas Martius and Teixeira Coelho in Brazil also 
showed similar pattern  of  lipid  abnormalities. 
INFLUENCE OF SOCIO-ECONOMIC STATUS. 
           The mean TC, TG and LDL are high and mean   HDL values are 
low among SES class 2&3 hypertensive patients when compared with 
hypertensive patients of SES class 4&5 (p values TC- 0.00052, TG- 0.22, 
LDL- 0.0186  and HDL- 0.0132), all these values are significant except  for  
TG.  The  percentage  of prevalence also showed   similar   pattern.  The  
high  prevalence  of  dyslipidemia   in h igh  socio-economic group is 
probably due to their sedentary life style and increased intake of fatty 
foods. 
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INFLUENCE OF STAGES OF HYPERTENSION. 
     Comparison of  lipid  profile  of  stage - І  hypertensive  patients  with  
stage - Π hypertensive patients did not show any significant difference  in  
mean  values  and percentage prevalence. A study conducted by S.Sharif, 
A.Cheema and M.Khan73 at Lahore   showed   significantly   high   values   
of   TC   and   LDL  among stage-П hypertensive but no significant 
difference in mean values of HDL and TG. 
INFLUENCE OF PRE-DIABETIC STATE. 
             The lipid profile of hypertensive patients with their blood sugar 
values in pre – diabetic   range  showed  high   mean values of TC, TG, 
LDL and HDL when compared   with  the   values   of   hypertensive   
patients  with normal blood sugar. Among these only TC was significantly 
high. 
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        CONCLUSIONS 
1. Hypertensive patients have significantly higher levels of all forms 
of cholesterol and higher percentage of individuals in dyslipidemic state 
when compared with normotensive persons. 
2. Hypertensive females have significantly higher levels of HDL c 
when        compared to hypertensive males. 
3. Elderly hypertensives have significantly high total cholesterol 
values when compared with young and middle aged hypertensives. 
4. Smoking have a significant impact on the lipid profile of 
hypertensives. 
5. Obesity when calculated using Body Mass Index and Waist 
Circumference correlates positively with abnormal lipid profile in 
hypertensives, whereas the Waist Hip Ratio does not show any correlation. 
6. Hypertensives who are sedentary and and in high Socio Economic 
Status have high prevalence of dyslipidemia. 
7. The stage of hypertension does not alter the lipid profile in 
hypertensives. 
8. Pre-Diabetic state significantly increases the total cholesterol in 
hypertensive patients. 
  
65 
 
 
LIMITATIONS 
1. The sample size is small. 
2. The design of the study is cross sectional. 
3.  The impact of treatment of dyslipidemia on hypertension and vice 
versa could not be studied longitudinally. 
4. Since most of the patients who attend the hospital OP department 
belong to low socio economic group, the pattern of dyslipidemia in high 
socio economic group could not be studied. 
5. Chances of confounding biases are more. 
6. The emerging risk factors like Lipoprotein (a) and LDL c sub-
fractions are not included in the study. 
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ABBREVIATIONS 
 
ATP II                          - Adult treatment and panel  III 
BP                                 - Blood Pressure 
BUN                             - Blood Urea Nitrogen 
BMI                              - Body mass Index 
CAD                             - Coronary Artery Disease  
CHD                             - Coronary  Heart  Disease 
CVA                             - Cerebrovascular Accident 
ECG                             - Electrocardiography 
ESRD                           - End Stage Renal Disease  
ET                                - Endothelin 
FBS                              - Fasting blood sugar 
FFA                              - Free Fatty Acid 
HDL-c                          - High Density lipoprotein Cholesterol 
IHD                              - Ischemic Heart Disease. 
LDL-c                          - Low Density Lipoprotein Cholesterol 
MRFIT                        - Multiple risk factor intervention trial. 
NO                               - Nitric Oxide. 
SBP                              - Systolic Blood pressure. 
SES                              - Socio Economic Status  
TC                                - Total Cholesterol 
TG                                - Triglycerides 
TIA                              - Transient Ischemic Attack 
VLDL                          - Very Low Density Lipoprotein  
WHR                           - Waist Hip Ratio 
 
 
 
 
LIPID PROFILE IN HYPERTENSIVE PATIENTS 
PROFOMA 
        Case       
Control     
 
 
No:        HT OP No: 
Name:        Age:   Sex: 
Address:                  Phone No: 
 
Socio-Economic status : (by modified Kuppuswamy scale) 
 
Class I II III IV V 
 
Life style : (physical activity < 2 MET hour / day) 
Sedentary Non Sedentary 
 
H/O smoking : (> 5 cigarettes / day) 
Yes No 
 
Family H/o Hypertension 
Father Mother Siblings 
 
    Anthropometry 
Height (in cm) Weight (in kg) BMI 
Waist (in cm) Hip ( in cm) WHR 
 Blood Pressure 
            Sitting R UL 
 
L UL
            Supine   
 
Investigations      Lipid profile 
Blood Sugar       TC - 
Fasting -       HDL - 
PP -                 LDL - 
B. Urea -                VLDL- 
S. Creatinine -      TG - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified (2007 ) Kuppuswamy socioeconomic status scale 
 
EDUCATION                                           OCCUPATION 
 
Profession / Honors 7   Profession 10  
Graduate / PG 6   Semi – profession 6  
Post high school / 
diploma 
5   Clerical / shop owner/ 
farmer 
5  
High school certificate 4   Skilled worker 4  
Mid school certificate 3   Semi skilled worker 3  
Primary certificate 2   Unskilled worker 2  
Illiterate 1   Unemployed 1  
  
Family income / month 
 
>  19575  12   Total 
Points 
  Class 
9788- 19574 10    26 - 29 Upper – I 
7323 – 9787 6    16 - 25 Upper middle - II 
4894 – 7322 4    11 - 15 Lower middle - III 
2936 – 4893 3      5 - 10 Upper lower – IV 
980 – 2935  2       < 5  Lower V 
< 980 1   Patients  points  class
 
 
 
 
 
Physical activity assessment 
 
Activity MET Duration MET 
calculation 
Washing / House keeping/ driving / 
cooking 
1-2   
Carpentry / walking (4mph) / Dancing 3-5   
Bigging in garden / Tennis games / 
swimming / cycling 10mph 
5-7   
Tracking / jogging 7-9   
Carrying loads / walking uphill / 
running 
>9   
Total MET    
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MASTER CHART – CASES .TOTAL NO -  107 
 
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
1 50 M 5 N - 170 60 20.76125 91 98 0.928571
2 56 M 5 N - 158 65 26.03749 102 100 1.02 
3 51 M 5 N - 168 56 19.84127 88 94 0.93617 
4 49 M 4 N - 172 62 20.95727 98 109 0.899083
5 57 M 5 N - 160 66 25.78125 87 102 0.852941
6 60 M 4 S - 170 86 29.75779 106 108 0.981481
7 57 M 5 N - 170 61 21.10727 88 108 0.814815
8 49 M 4 N - 160 79 30.85938 104 102 1.019608
9 51 M 5 S - 168 80 28.34467 110 102 1.078431
10 60 M 4 N - 171 63 21.54509 92 98 0.938776
11 68 M 3 S - 167 76 27.25089 103 101 1.019802
12 68 M 4 N - 170 63 21.79931 92 98 0.938776
13 67 M 3 S - 158 68 27.23922 116 109 1.06422 
14 71 M 4 N - 164 56 20.82094 88 96 0.916667
15 62 M 3 N - 161 74 28.54828 109 112 0.973214
16 62 M 4 N - 174 62 20.47827 92 99 0.929293
17 63 M 3 N - 162 63 24.00549 90 98 0.918367
18 64 M 4 N - 170 65 22.49135 86 96 0.895833
19 62 M 3 N - 154 64 26.986 92 98 0.938776
20 67 M 5 S - 158 65 26.03749 106 104 1.019231
21 75 M 3 N - 164 58 21.56454 103 105 0.980952
22 63 M 5 S - 160 72 28.125 112 108 1.037037
23 53 M 3 N + 169 60 21.00767 86 99 0.868687
24 52 M 4 S + 162 70 26.67276 98 104 0.942308
25 46 M 5 S + 170 88 30.44983 116 118 0.983051
26 47 M 3 S + 170 61 21.10727 88 96 0.916667
27 62 M 3 S + 164 78 29.00059 110 118 0.932203
28 72 M 4 N + 159 66 26.10656 94 98 0.959184
29 61 M 4 N + 158 75 30.04326 98 106 0.924528
30 71 M 3 N + 164 65 24.16716 92 108 0.851852
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
31 75 M 4 S + 160 85 33.20313 106 111 0.954955
32 65 M 3 S + 158 65 26.03749 98 104 0.942308
33 73 M 4 N + 163 72 27.09925 113 120 0.941667
34 63 M 3 S + 156 65 26.7094 104 106 0.981132
35 63 M 2 S + 160 70 27.34375 89 91 0.978022
36 41 M 2 S - 168 70 24.80159 96 96 1 
37 42 M 2 S - 164 80 29.7442 96 102 0.941176
38 31 M 2 S - 172 75 25.35154 99 102 0.970588
39 53 M 2 S - 164 72 26.76978 92 99 0.929293
40 44 M 2 S - 163 57 21.45357 81 89 0.910112
41 52 M 2 S - 166 79 28.66889 103 103 1 
42 31 M 2 N - 170 64 22.14533 86 96 0.895833
43 36 M 3 N + 168 75 26.57313 85 96 0.885417
44 40 M 3 N + 167 75 26.89232 102 103 0.990291
45 58 M 3 N + 154 61 25.72103 89 92 0.967391
46 65 M 3 S - 154 64 26.986 100 112 0.892857
47 32 M 3 S - 171 84 28.72679 96 102 0.941176
48 42 M 3 S + 163 67 25.21736 84 93 0.903226
49 54 M 3 S + 159 65 25.71101 104 108 0.962963
50 63 M 3 S + 157 65 26.37024 104 109 0.954128
51 38 M 4 S + 166 80 29.03179 106 101 1.049505
52 56 M 4 S + 154 62 26.14269 96 96 1 
53 69 M 4 N - 163 60 22.58271 88 90 0.977778
54 39 M 4 N - 173 80 26.72993 95 102 0.931373
55 34 M 4 N + 163 70 26.34649 96 110 0.872727
56 46 M 5 N - 162 72 27.43484 94 99 0.949495
57 37 M 5 S - 154 50 21.08281 78 89 0.876404
58 73 M 5 S - 165 72 26.44628 106 118 0.898305
59 72 F 4 N - 146 60 28.14787 98 100 0.98 
60 58 F 4 N - 153 58 24.7768 80 92 0.869565
  
 
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
61 57 F 4 N - 153 71 30.33021 94 113 0.831858
62 40 F 4 N - 160 97 37.89063 103 117 0.880342
63 67 F 4 N - 146 50 23.45656 90 106 0.849057
64 50 F 4 N - 163 57 21.45357 84 110 0.763636
65 65 F 4 N - 152 57 24.67105 80 91 0.879121
66 65 F 4 S - 153 58 24.7768 80 90 0.888889
67 67 F 4 S - 146 58 27.20961 98 100 0.98 
68 68 F 4 S - 145 83 39.47681 107 120 0.891667
69 66 F 4 S - 156 60 24.65483 86 100 0.86 
70 37 F 4 S - 157 55 22.31328 83 95 0.873684
71 41 F 4 S - 160 56 21.875 85 105 0.809524
72 40 F 4 S - 154 61 25.72103 87 106 0.820755
73 38 F 4 S - 145 53 25.20809 82 96 0.854167
74 45 F 4 S - 152 76 32.89474 101 122 0.827869
75 68 F 5 S - 156 50 20.54569 86 100 0.86 
76 59 F 5 N - 167 65 23.30668 83 101 0.821782
77 74 F 5 N - 149 50 22.52151 82 103 0.796117
78 32 F 5 S - 147 55 25.45236 82 96 0.854167
79 48 F 5 S - 139 64 33.12458 105 120 0.875 
80 65 F 3 S - 148 50 22.82688 83 96 0.864583
81 62 F 3 S - 153 65 27.7671 88 95 0.926316
82 68 F 3 S - 145 85 40.42806 108 127 0.850394
83 63 F 3 N - 150 64 28.44444 85 83 1.024096
84 54 F 3 S - 138 70 36.75698 106 118 0.898305
85 39 F 3 S - 152 80 34.62604 100 108 0.925926
86 74 F 3 S - 153 60 25.63117 89 101 0.881188
87 63 F 3 S - 151 66 28.9461 98 100 0.98 
88 52 F 3 S - 150 65 28.88889 96 99 0.969697
89 30 F 3 S - 153 65 27.7671 85 99 0.858586
90 55 F 3 N - 145 85 40.42806 108 127 0.850394
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
91 60 F 2 S - 158 58 23.23346 87 101 0.861386
     92 70 F 2 S - 150 90 40 104 120 0.866667
93 67 F 2 S - 150 90 40 102 123 0.829268
94 71 F 2 S - 153 66 28.19428 100 101 0.990099
95 61 F 2 N - 150 66 29.33333 98 98 1 
96 69 F 2 N - 160 52 20.3125 82 103 0.796117
97 70 F 2 N - 153 60 25.63117 84 101 0.831683
98 52 F 2 S - 150 90 40 102 123 0.829268
99 55 F 2 S - 138 70 36.75698 106 124 0.854839
100 39 F 3 N - 159 72 28.47989 99 101 0.980198
101 54 F 3 S - 152 80 34.62604 100 120 0.833333
102 39 F 3 N - 147 85 39.33546 82 96 0.854167
103 48 F 4 N - 150 62 27.55556 89 106 0.839623
104 45 F 4 N - 147 55 25.45236 83 96 0.864583
105 60 F 5 N - 146 65 30.49353 95 103 0.92233 
106 70 F 2 S - 148 60 27.39226 87 109 0.798165
107 60 F 5 N - 146 65 30.49353 95 103 0.92233 
 
 
 
 
 
 
 
  
 
SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
1 148 96 1 97 132 N 163 30 101 32.2 156 
2 166 80 2 99 158 Y 213 32 137 44.1 222 
3 150 80 1 97 129 N 179 38 102 39 195 
4 160 100 2 81 96 N 169 31 103 35.4 177 
5 150 88 1 94 118 N 177 35 103 39 197 
6 170 88 2 94 136 N 199 38 112 49 245 
7 156 96 1 81 103 N 161 29 99 33.2 166 
8 170 86 2 107 127 Y 200 33 135 42 210 
9 180 88 2 113 141 Y 201 41 126 34 170 
10 170 90 2 103 114 Y 179 28 102 49 250 
11 164 90 2 107 154 Y 191 41 127 23 115 
12 156 94 1 101 151 Y 185 41 124 20.2 101 
13 162 86 2 107 136 Y 216 38 138 40 200 
14 168 88 2 91 97 N 164 28 116 26.2 131 
15 166 90 2 99 157 Y 204 38 130 36 180 
16 156 80 1 103 131 N 183 31 120 32 160 
17 162 90 2 91 107 N 181 30 121 30 151 
18 150 80 1 96 128 N 160 29 100 31.2 156 
19 160 80 2 86 114 N 191 38 104 49 245 
20 164 86 2 102 144 Y 204 32 131 43.2 216 
21 170 88 2 93 97 N 171 33 105 33.4 167 
22 180 90 2 82 107 N 173 28 99 47 235 
23 156 80 1 86 98 N 169 30 82 57 286.4 
24 150 86 1 103 136 Y 264 44 183 37 186 
25 170 90 2 96 117 N 217 40 105 72 302 
26 164 80 2 114 142 Y 207 48 103 56 179 
27 174 96 2 96 132 N 209 40 128 40.6 203 
28 158 98 1 93 103 N 216 32 142 42 210 
29 168 106 2 112 136 Y 220 40 133 47 235 
30 156 86 1 81 93 N 216 30 140 46.2 231 
SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
31 168 110 2 91 99 N 283 41 187 57 285 
32 164 106 2 94 149 Y 268 40 169 59 295 
33 156 90 1 78 113 N 216 30 138 48 240 
34 144 100 2 88 98 N 244 36 171 37 185 
35 150 70 1 104 145 Y 202 47 143 12 58 
36 150 90 1 80 106 N 206 40 131 35 175 
37 130 100 2 93 124 N 182 31 121 30 150 
38 150 90 1 96 112 N 176 28 99 49 246 
39 144 90 1 96 114 N 218 37 139 42 210 
40 150 100 2 111 143 Y 237 40 154 43 215 
41 150 90 1 96 130 N 206 38 133 35 175 
42 160 110 2 96 110 N 188 41 124 23 115 
43 160 100 2 86 117 N 188 34 119 45 225 
44 180 120 2 88 119 N 179 36 112 31 155 
45 160 100 2 108 162 Y 206 48 117 40.6 203 
46 154 96 1 91 136 N 202 42 124 36 180 
47 150 90 1 86 141 Y 205 33 130 42 209 
48 150 110 2 120 176 Y 190 31 69 90 451 
49 164 96 2 101 156 Y 192 43 77 72.2 361 
50 160 90 2 110 158 Y 258 44 159 55 275 
51 160 100 2 108 153 Y 198 45 111 42 212 
52 190 140 2 109 122 Y 208 48 123.4 32.6 163 
53 176 106 2 84 128 N 173 35 103 35.4 177 
54 150 80 1 96 117 N 189 38 102 49 125 
55 184 96 2 99 126 N 185 38 117 39.2 196 
56 140 110 2 88 190 Y 152 28 98 26 130 
57 144 96 1 94 126 N 162 29 100 33.2 166 
58 180 86 2 101 146 Y 215 46 123 46.2 231 
59 200 100 2 123 188 Y 184 38 108 37.2 188 
60 156 88 1 96 107 N 175 46 104 29 145 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
61 170 100 2 72 108 N 185 38 109 38 190 
62 150 100 2 76 110 N 189 35 120 34 170 
63 190 90 2 91 105 N 180 34 108 38 190 
64 160 100 2 96 119 N 185 38 109 38 190 
65 158 86 1 99 117 N 180 45 104 29 145 
66 150 86 1 98 126 N 180 43 104 33 165 
67 160 100 2 86 126 N 190 38 115 37.2 185 
68 170 80 2 102 132 Y 207 45 126 36.4 182 
69 168 106 2 98 120 N 179 29 107 43 215 
70 176 90 2 88 120 N 170 33 105 32.2 161 
71 148 86 1 92 115 N 175 40 104 31 155 
72 148 80 1 80 117 N 175 40 104 31.4 157 
73 158 98 1 90 120 N 183 47 101 34.1 171 
74 160 98 2 98 146 Y 230 44 158 28 140 
75 160 100 2 98 120 N 171 29 104 37.6 188 
76 170 98 2 96 130 N 159 34 99 25.8 129 
77 170 100 2 96 130 N 158 24 100 34 120 
78 160 110 2 92 117 N 187 48 105 34 170 
79 158 98 1 106 156 Y 208 44 64 99 495 
80 180 90 2 98 120 N 174 33 109 32 160 
81 172 98 2 88 102 N 196 45 118 33 166 
82 150 90 1 97 105 N 205 44 127 34.4 172 
83 170 106 2 98 140 Y 194 44 117 33 166 
84 150 98 1 90 120 N 212 44 68 98.4 493 
85 160 96 2 106 126 Y 235 45 159 31 155 
86 190 80 2 90 128 N 216 42 123 51 255 
87 160 90 2 98 107 N 206 40 130 36 180 
88 160 90 2 96 103 N 207 41 130 36 180 
89 170 110 2 96 112 N 195 45 117 33 166 
90 150 90 1 96 106 N 206 45 126 34.4 172 
  SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
91 170 90 2 96 130 N 150 30 94 25.8 129 
92 164 90 2 90 120 N 273 43 190 39.2 196 
93 160 80 2 106 148 Y 253 33 190 29.2 146 
94 192 80 2 90 132 N 220 44 125 51 255 
95 164 86 2 88 96 N 208 39 133 36.8 184 
96 170 106 2 98 140 Y 166 26 102 37.6 188 
97 190 80 2 96 114 N 218 44 123 51 255 
98 164 90 2 88 120 N 263 43 190 29.2 146 
99 160 100 2 96 127 N 210 46 64 99 493 
100 170 100 2 99 132 N 156 34 96 25.8 128 
101 160 110 2 80 121 N 233 47 159 27 135 
102 160 110 2 92 128 N 185 50 101 34 170 
103 142 80 1 85 127 N 172 41 100 31 155 
104 180 100 2 99 126 N 172 35 109 32 160 
105 170 110 2 112 136 N 169 29 102 38 188 
106 180 100 2 92 104 N 235 53 143 39 195 
107 170 110 2 112 146 Y 169 29 102 37.6 188 
MASTER CHART – NORMOTENSIVE CONTROLS NO - 60 
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
1 65 M 3 S  N 164 66 24.53896 98 99 0.989899
2 39 M 3  S N 168 60 21.2585 98 103 0.951456
3 54 M 3  N N 166 82 29.75758 91 108 0.842593
4 40 M 3  S N 157 60 24.34176 89 97 0.917526
5 41 M 3  S N 164 75 27.88519 91 100 0.91 
6 31 M 2  N N 167 62 22.23099 80 89 0.898876
7 63 M 4  S Y 164 60 22.30815 90 101 0.891089
8 61 M 4  S N 172 60 20.28123 88 96 0.916667
9 66 M 5  N N 159 57 22.54658 91 103 0.883495
10 61 M 3  S Y 164 80 29.7442 93 110 0.845455
11 73 M 3  S N 172 70 23.66144 93 99 0.939394
12 71 M 3  N N 168 70 24.80159 96 99 0.969697
13 54 M 4  N Y 160 58 22.65625 96 106 0.90566 
14 44 M 4  S Y 164 54 20.07733 96 102 0.941176
15 41 M 4  N Y 168 74 26.21882 97 114 0.850877
16 62 M 4  N N 184 58 17.13138 79 89 0.88764 
17 33 M 4  N N 168 73 25.86451 96 108 0.888889
18 62 M 4  N N 174 62 20.47827 94 99 0.949495
19 60 M 4  N Y 170 72 24.91349 94 106 0.886792
20 51 M 5  N N 166 70 25.40282 96 110 0.872727
21 50 M 5  N N 174 60 19.81768 92 100 0.92 
22 60 M 5  N N 168 70 24.80159 97 112 0.866071
23 69 M 3  S N 162 60 22.86237 98 114 0.859649
24 54 M 4  N N 156 54 22.18935 94 104 0.903846
25 52 M 5  N N 174 61 20.14797 86 91 0.945055
26 53 M 5  S Y 164 56 20.82094 90 103 0.873786
27 52 M 5  S Y 156 54 22.18935 96 98 0.979592
28 64 M 3  S Y 169 62 21.70792 82 88 0.931818
29 67 M 2  S N 168 76 26.92744 98 104 0.942308
30 61 M 2  S Y 168 70 24.80159 106 117 0.905983
 
  
 
SL.NO AGE SEX SES LS SMOKING HEIGHT WEIGHT BMI WAIST HIP WHR 
31 62 M 3  S Y 182 60 18.11375 81 93 0.870968
32 46 M 3  S Y 168 72 25.5102 90 102 0.882353
33 48 M 2  S Y 172 70 23.66144 108 117 0.923077
34 68 F 5  N N 170 68 23.52941 98 109 0.899083
35 74 F 5  N N 169 69 24.15882 102 101 1.009901
36 48 F 5  N N 160 68 26.5625 96 112 0.857143
37 69 F 3  S N 170 63 21.79931 94 100 0.94 
38 39 F 3  N N 156 60 24.65483 80 94 0.851064
39 33 F 3  S N 146 50 23.45656 88 96 0.916667
40 74 F 3  S N 158 63 25.23634 84 98 0.857143
41 93 F 4  N N 140 50 25.5102 85 96 0.885417
42 61 F 4  N N 158 65 26.03749 98 102 0.960784
43 51 F 4  S N 152 60 25.96953 80 92 0.869565
44 45 F 4  S N 150 57 25.33333 88 98 0.897959
45 55 F 4  S N 158 62 24.83576 84 99 0.848485
46 67 F 4  N N 162 66 25.14861 108 119 0.907563
47 48 F 2  S N 161 76 29.31986 112 118 0.949153
48 39 F 2  N N 156 70 28.76397 91 103 0.883495
49 35 F 2  S N 146 58 27.20961 86 106 0.811321
50 31 F 2  S N 159 62 24.52435 84 98 0.857143
51 70 F 4  N N 171 68 23.25502 101 114 0.885965
52 63 F 4  N N 164 56 20.82094 88 98 0.897959
53 46 F 3  S N 166 59 21.41094 96 98 0.979592
54 61 F 4  S N 168 71 25.1559 94 107 0.878505
55 59 F 4  S N 148 50 22.82688 84 117 0.717949
56 49 F 4  S N 148 50 22.82688 85 96 0.885417
57 57 F 3  S N 148 54 24.65303 82 88 0.931818
58 60 F 3  S N 160 60 23.4375 83 100 0.83 
59 65 F 3  N N 162 62 23.62445 99 105 0.942857
60 63 F 4  N N 156 70 28.76397 112 115 0.973913
SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
1 132 80 0 106 132 Y 169 41 115 13.2 66 
2 120 80 0 86 98 N 168 42 106 29.2 146 
3 130 80 0 94 98 N 176 56 10 13.4 67 
4 120 80 0 77 110 N 154 39 87 28 140 
5 120 80 0 98 106 N 166 29 110 27 135 
6 110 70 0 89 97 N 177 37 102 38.6 193 
7 128 86 0 92 114 N 172 59 93 20 100 
8 130 82 0 86 107 N 137 37 86 14 68 
9 116 80 0 87 114 N 156 41 89 26 130 
10 136 80 0 96 104 N 169 56 99 13.4 68 
11 122 86 0 94 120 N 166 39 104 23 115 
12 122 80 0 93 199 Y 160 42 98 29.2 146 
13 124 82 0 101 129 Y 162 39 100 23 116 
14 120 80 0 90 114 N 164 40 104 29 145 
15 120 80 0 84 119 N 166 29 104 33 164 
16 120 80 0 89 112 N 160 44 94 21.6 108 
17 120 86 0 96 98 N 134 41 81 12 60 
18 124 84 0 99 114 N 127 41 68 18 90 
19 124 80 0 90 90 N 130 40 80 10 40 
20 124 82 0 90 106 N 160 48 93 19 95 
21 118 78 0 79 89 N 129 41 67 21 105 
22 122 84 0 89 99 N 138 41 83 15 75 
23 120 80 0 102 132 Y 160 39 99 22 110 
24 120 78 0 98 130 N 160 40 97 23.2 116 
25 124 78 0 91 115 N 139 39 84 16 78 
26 120 80 0 90 116 N 170 57 91 22 110 
27 130 80 0 90 112 N 171 41 117 31 65 
28 114 70 0 90 96 N 177 42 97 38 193 
29 126 82 0 88 126 N 165 48 95 22 110 
30 126 80 0 104 126 Y 180 48 104 28 140 
 
 
                                   
 
 
 
SL.NO SBP DBP STAGE FBS PPBS IFG/IGT TC HDL LDL VLDL TG 
31 120 76 0 93 114 N 162 44 96 21 110 
32 116 80 0 99 115 N 164 31 114 27 135 
33 120 84 0 98 129 N 182 48 107 27 135 
34 128 86 0 98 114 N 137 22 94 21.4 107 
35 130 80 0 95 126 N 142 40 84 18 88 
36 124 80 0 99 100 N 154 35 92 26.6 133 
37 120 80 0 78 116 N 181 37 126 18.4 92 
38 110 80 0 99 105 N 186 42 108 36 180 
39 120 80 0 90 106 N 174 44 107 23.2 116 
40 130 80 0 91 100 N 196 49 127 20.2 101 
41 120 80 0 86 112 N 166 46 100 20 100 
42 120 82 0 99 121 N 156 35 94 2608 134 
43 122 82 0 98 128 N 172 41 100 31 155 
44 122 80 0 92 112 N 172 35 104 33.2 166 
45 110 70 0 98 115 N 176 42 98 36 180 
46 136 86 0 102 146 Y 162 45 85 31.6 158 
47 134 80 0 116 164 Y 244 36 171 37 185 
48 130 80 0 106 154 Y 198 49 115 34.2 171 
49 126 86 0 96 114 N 207 49 132 26 130 
50 132 86 0 91 136 N 195 42 120 33 166 
51 128 88 0 91 99 N 150 48 89 13 64 
52 132 86 0 84 108 N 160 39 101 20 99 
53 134 86 0 86 98 N 185 48 121 16 78 
54 130 80 0 70 126 N 158 48 90 20 100 
55 122 86 0 98 122 N 205 49 130 26 130 
56 124 80 0 84 114 N 166 46 98 22 110 
57 120 82 0 88 120 N 174 48 99 26.2 121 
58 130 82 0 93 104 N 196 59 117 20.2 101 
59 134 86 0 89 110 N 142 45 78 19 94 
60 136 88 0 124 164 Y 129 21 52 55.8 279 
